Literature DB >> 19357404

Efficacy of esomeprazole for treatment of poorly controlled asthma.

John G Mastronarde, Nicholas R Anthonisen, Mario Castro, Janet T Holbrook, Frank T Leone, W Gerald Teague, Robert A Wise.   

Abstract

BACKGROUND: Gastroesophageal reflux is common among patients with asthma but often causes mild or no symptoms. It is not known whether treatment of gastroesophageal reflux with proton-pump inhibitors in patients who have poorly controlled asthma without symptoms of gastroesophageal reflux can substantially improve asthma control.
METHODS: In a parallel-group, double-blind trial, we randomly assigned 412 participants with inadequately controlled asthma, despite treatment with inhaled corticosteroids, and with minimal or no symptoms of gastroesophageal reflux to receive either 40 mg of esomeprazole twice a day or matching placebo. Participants were followed for 24 weeks with the use of daily asthma diaries, spirometry performed once every 4 weeks, and questionnaires that asked about asthma symptoms. We used ambulatory pH monitoring to ascertain the presence or absence of gastroesophageal reflux in the participants. The primary outcome was the rate of episodes of poor asthma control, as assessed on the basis of entries in asthma diaries.
RESULTS: Episodes of poor asthma control occurred with similar frequency in the placebo and esomeprazole groups (2.3 and 2.5 events per person-year, respectively; P=0.66). There was no treatment effect with respect to individual components of the episodes of poor asthma control or with respect to secondary outcomes, including pulmonary function, airway reactivity, asthma control, symptom scores, nocturnal awakening, or quality of life. The presence of gastroesophageal reflux, which was documented by pH monitoring in 40% of participants with minimal or no symptoms, did not identify a subgroup of patients that benefited from treatment with proton-pump inhibitors. There were fewer serious adverse events among patients receiving esomeprazole than among those receiving placebo (11 vs. 17).
CONCLUSIONS: Despite a high prevalence of asymptomatic gastroesophageal reflux among patients with poorly controlled asthma, treatment with proton-pump inhibitors does not improve asthma control. Asymptomatic gastroesophageal reflux is not a likely cause of poorly controlled asthma. (ClinicalTrials.gov number, NCT00069823.) 2009 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19357404      PMCID: PMC2974569          DOI: 10.1056/NEJMoa0806290

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  40 in total

1.  Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease.

Authors:  Kenneth R DeVault; Donald O Castell
Journal:  Am J Gastroenterol       Date:  2005-01       Impact factor: 10.864

2.  Standardisation of spirometry.

Authors:  M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

3.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

Review 4.  Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease.

Authors:  C Donnellan; N Sharma; C Preston; P Moayyedi
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

5.  Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms.

Authors:  Michael R Littner; Felix W Leung; E David Ballard; Bidan Huang; Nina K Samra
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

6.  Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial.

Authors:  Toni O Kiljander; Susan M Harding; Stephen K Field; Mark R Stein; Harold S Nelson; Jan Ekelund; Marta Illueca; Ola Beckman; Mark B Sostek
Journal:  Am J Respir Crit Care Med       Date:  2005-12-15       Impact factor: 21.405

7.  The prevalence of gastroesophageal reflux disease in adult asthmatics.

Authors:  Toni O Kiljander; Jukka O Laitinen
Journal:  Chest       Date:  2004-11       Impact factor: 9.410

8.  Development and validation of the Mini Asthma Quality of Life Questionnaire.

Authors:  E F Juniper; G H Guyatt; F M Cox; P J Ferrie; D R King
Journal:  Eur Respir J       Date:  1999-07       Impact factor: 16.671

9.  Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire.

Authors:  Elizabeth F Juniper; Jean Bousquet; Linda Abetz; Eric D Bateman
Journal:  Respir Med       Date:  2005-10-13       Impact factor: 3.415

10.  Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index.

Authors:  D A Revicki; N K Leidy; F Brennan-Diemer; S Sorensen; A Togias
Journal:  Chest       Date:  1998-10       Impact factor: 9.410

View more
  86 in total

Review 1.  Update in asthma 2009.

Authors:  Wendy C Moore; Rodolfo M Pascual
Journal:  Am J Respir Crit Care Med       Date:  2010-06-01       Impact factor: 21.405

2.  Lansoprazole for children with poorly controlled asthma: a randomized controlled trial.

Authors:  Janet T Holbrook; Robert A Wise; Benjamin D Gold; Kathryn Blake; Ellen D Brown; Mario Castro; Allen J Dozor; John J Lima; John G Mastronarde; Marianna M Sockrider; W Gerald Teague
Journal:  JAMA       Date:  2012-01-25       Impact factor: 56.272

3.  Effect of Continuous Positive Airway Pressure on Airway Reactivity in Asthma. A Randomized, Sham-controlled Clinical Trial.

Authors:  Janet T Holbrook; Elizabeth A Sugar; Robert H Brown; Lea T Drye; Charles G Irvin; Alan R Schwartz; Robert S Tepper; Robert A Wise; Razan Z Yasin; Michael F Busk
Journal:  Ann Am Thorac Soc       Date:  2016-11

4.  Effect of obesity on asthma phenotype is dependent upon asthma severity.

Authors:  Stacy Raviv; Anne E Dixon; Ravi Kalhan; David Shade; Lewis J Smith
Journal:  J Asthma       Date:  2010-11-22       Impact factor: 2.515

5.  Effects of obstructive sleep apnea and gastroesophageal reflux disease on asthma control in obesity.

Authors:  Anne E Dixon; Emmanuelle M Clerisme-Beaty; Elizabeth A Sugar; Rubin I Cohen; Jason E Lang; Ellen D Brown; Joel E Richter; Charles G Irvin; John G Mastronarde
Journal:  J Asthma       Date:  2011-08-08       Impact factor: 2.515

Review 6.  Medical Therapy of Gastroesophageal Reflux Disease Beyond Proton Pump Inhibitors: Where Are We Heading?

Authors:  Herbert Koop
Journal:  Visc Med       Date:  2018-03-29

Review 7.  The adult asthmatic.

Authors:  Amir A Zeki; Nicholas J Kenyon; Ken Yoneda; Samuel Louie
Journal:  Clin Rev Allergy Immunol       Date:  2012-08       Impact factor: 8.667

8.  Coexisting chronic conditions associated with mortality and morbidity in adult patients with asthma.

Authors:  Kaharu Sumino; Katiuscia O'Brian; Brian Bartle; David H Au; Mario Castro; Todd A Lee
Journal:  J Asthma       Date:  2014-01-27       Impact factor: 2.515

9.  Insight Into the Relationship Between Gastroesophageal Reflux Disease and Asthma.

Authors:  Fehmi Ates; Michael F Vaezi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-11

Review 10.  Obesity in asthma: approaches to treatment.

Authors:  Shyamala Pradeepan; Garth Garrison; Anne E Dixon
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.